Welcom to Sichuan Hengkang Science and Technology Development Co.,Ltd.
Other Heterocyclic Compounds
Advanced Drug Intermediates
Intermediates of Ibrutinib
Intermediates of Ozanimod
Intermediates of Upadacitinib
Intermediates of Zanubrutinib
Protected Amino acids
New TOP10 forecast for a bestseller in 2022
by admin on 22-02-23
Recently, the Nature subsidiary magazine Nature Review Drug Discovery and the biomedical industry media Evaluate Vantage have both published articles on the analysis and prediction of the global drug sales of Top10 in 2022. Two analysis article gives the same forecast, in the list, there are two ...
2022 Spring Festival Holiday notice
by admin on 22-01-19
Dear Customer: The Spring Festival of 2022 is coming. Combined with the equipment maintenance situation of the production workshop of our company, the company has decided that the 2022 Spring Festival holiday will be notified as follows: I. Production Department from January 19, 2022 to Februar...
The AI auxiliary design drug pipeline has entered the IND-Enabling Studies stage within 8 months
by admin on 22-01-19
On January 17,2022, focusing on the use of artificial intelligence driven drug development announced, use its independent research and development of integrated AI new drug discovery platform Molecule Pro, in 8 months to design, verified 69 new small molecules and obtained for a class B G protein...
The latest study: complete vaccination can not prevent Oikjon, strengthening needle efficiency is only 37%
by admin on 22-01-10
Before many people get the third shot, a new warning from the Moderna CEO comes here.Recently, he said publicly that as the drug effectiveness will decline over time, people may need a fourth dose in the fall to boost protection. Stephane Bancel said people receiving booster needles last fall ma...
Pfizer says it expects COVID-19 pandemic to last until 2024
by admin on 21-12-21
Pfizer recently predicted that the COVID-19 pandemic will continue to last for one to two years in some parts of the world, and may fall to “endemic pandemic” (Endemic) levels in others during the same period.By 2024, the novel coronavirus is expected to be controlled globally, and wi...
After a 5.8 billion yuan order, Kellein listed in Hong Kong on October 10
by admin on 21-12-14
On December 10, The a-share long Bull Kelaiying was officially listed on the Hong Kong Stock Exchange, offering 18.415,400 shares at HK $388 per share. This means that Kelaiin has officially achieved dual listing in A+H following other CXO peers such as pharmatech, Tiger...
PerkinElmer completes $5.25bn acquisition of antibody specialist
by admin on 21-11-08
PerkinElmer has completed its acquisition of BioLegend, a worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion. The acquisition, the largest in PerkinElmer’s history, further expands the company’s life science franchise i...
Hit enter to search or ESC to close